Publication|Articles|September 24, 2025
Supplements and Featured Publications
- Long-Acting Injectable Administration In Schizophrenia With Insights From Genoa Healthcare® Pharmacy
Long-Acting Injectable Program Implementation Insights From Genoa Healthcare® Pharmacy
Listen
0:00 / 0:00
Advertisement
This educational resource was sponsored by Johnson & Johnson.
Part 2 of this educational resource provides insights for institutions seeking to implement a pharmacist-led long-acting injectable administration program for schizophrenia.
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease
3
Experts, Patients Highlight Barriers to Arthritis Care Amid World Arthritis Day Observance
4
Medical School Diversity Declines Following Affirmative Action Repeal
5